Back to top
more

Avanos Medical (AVNS)

(Delayed Data from NYSE)

$21.18 USD

21.18
349,233

+1.79 (9.23%)

Updated Jul 11, 2024 04:00 PM ET

After-Market: $21.18 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (153 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Avanos Medical (AVNS) Down 2.2% Since Last Earnings Report?

by Zacks Equity Research

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Avanos Medical (AVNS) Q2 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.

What's in Store for Senseonics Holdings' (SENS) Q2 Earnings?

by Zacks Equity Research

Senseonics Holdings' (SENS) second-quarter results are likely to gain from higher sales outside the United States.

DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect strong segmental performance.

Avanos Medical (AVNS) Q2 Earnings Miss Estimates

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of -8.70% and 2.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in Pharmaceutical segment.

McKesson (MCK) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

AmerisourceBergen (ABC) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal third-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Avanos Medical (AVNS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Avanos Medical (AVNS) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Avanos Medical (AVNS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Cerner (CERN) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Cerner's (CERN) second-quarter results are likely to reflect gains from strategic deals.

What's in Store for West Pharmaceutical's (WST) Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.

Baxter (BAX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) second-quarter results are likely to reflect growth in its Acute Therapies business.

PerkinElmer (PKI) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

PerkinElmer's (PKI) second-quarter results are likely to reflect strong performance at Diagnostics segment.

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

What's in Store for Intuitive Surgical's (ISRG) Q2 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance at Instruments & Accessories segment.

Here's Why You Should Retain Avanos (AVNS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Here's Why You Should Hold on to Avanos (AVNS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS), owing to its strong product line and focus on its R&D.

Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the first quarter.

Avanos Medical (AVNS) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of 27.78% and 2.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avanos Medical (AVNS) Down 1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Avanos Medical (AVNS) Stock Now

by Zacks Equity Research

Investor confidence is high in Avanos Medical (AVNS) stock, courtesy of its solid prospects.

Avanos Medical (AVNS) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the fourth quarter.